ANIX
Anixa Biosciences, Inc.
Set alert
- YTD
- 0.00%
- 1 year
- -23.15%
- Open
- 3.28
- Prev close
- 3.30
- Mkt cap
- 108.46M
- Vol
- 140.66K
- Avg vol
- 279.08K
- EPS
- -0.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.10
- High
- 3.35
- Forward P/E
- -7.17
- Beta
- 0.85
- Short ratio
- 3.03
- Inst. own
- 17.46%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 21, 2025
- 50-d avg
- 3.17
- 200-d avg
- 3.04
- 1y target
- 8.50
Key statistics
- Market cap
- 83.02M
- Enterprise value
- 64.97M
- Trailing P/E
- 0.00
- Forward P/E
- -7.17
- PEG ratio
- 0.00
- Price / book
- 3.81
- EPS (TTM)
- -0.39
- Beta
- 0.85
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -4.30M
- Total cash
- 20.75M
- Total debt
- 237.00K
- Return on equity
- -55.24%
- Shares outstanding
- 32.18M
- Short % of float
- 1.91%
- 50-day average
- 3.17
- 200-day average
- 3.04
Analyst view
Consensus: none
- Target (low)
- 7.00
- Target (mean)
- 8.50
- Target (high)
- 10.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Jan 21, 2025
Expected Jan 21, 2025. Consensus EPS estimate -0.11.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 21, 2025 | Oct 1, 2024 | -0.11 | — | — | — |
| Sep 6, 2024 | Jul 1, 2024 | -0.11 | -0.10 | +0.01 | +9.09% |
| Jun 4, 2024 | Apr 1, 2024 | -0.11 | -0.10 | +0.01 | +9.09% |
| Mar 12, 2024 | Jan 1, 2024 | -0.09 | -0.10 | -0.01 | -11.11% |
| Jan 16, 2024 | Oct 1, 2023 | -0.09 | -0.09 | 0.00 | 0.00% |
| Sep 6, 2023 | Jul 1, 2023 | -0.09 | -0.08 | +0.01 | +11.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 11, 2024 | D. Boral Capital | main | Buy | Buy |
| Sep 30, 2024 | EF Hutton | main | Buy | Buy |
| Sep 24, 2024 | EF Hutton | main | Buy | Buy |
| Sep 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer. Its vaccine technologies focus on immunizing against retired proteins that found to be expressed in certain forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- anixa.com
News
- Anixa Biosciences (NASDAQ:ANIX) Share Price Breaks Below 200-Day Moving Average – Time to Sell?
- Anixa Biosciences Completes Dosing Of Fifth Group In Its Phase 1 Clinical Study Of FSHR-Targeted CAR-T Therapy To Treat Ovarian Cancer
- Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
- Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
- Anixa Biosciences Participant In Its Current Phase 1 Study Of FSHR-Targeted CAR-T Therapy For Recurrant Ovarian Cancer Demonstrates Stable Disease After 90 Days Of Treatment; Patient Was Treated In Fifth Dose Cohort
- Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
- Anixa Biosciences Announces Second Patient Has Been Treated In Fifth Cohort Of Its Ongoing Phase 1, Dose-Escalating, Clinical Trial Evaluating FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer
- Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
- Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Arnold Baskies Purchases 5,000 Shares
- Insider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Buys $19,460.00 in Stock
Your note
Sign in to keep a note on ANIX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASKIES ARNOLD M | Director | Purchase | Jul 25, 2024 | 115,000 |
| CATELANI MICHAEL J | President | Purchase | Jun 6, 2024 | 35,211 |
| KUMAR AMIT | Chief Executive Officer | Purchase | Jun 6, 2024 | 516,925 |
| TITTERTON LEWIS H JR | Director | Conversion of Exercise of derivative security | Oct 21, 2024 | 912,334 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.33% | 1,392,906 | 3.59M | Sep 29, 2024 |
| D.A. Davidson & Co. | 2.09% | 671,072 | 1.73M | Sep 29, 2024 |
| Laird Norton Wetherby Trust Company, LLC | 1.93% | 620,735 | 1.60M | Sep 29, 2024 |
| UBS Group AG | 1.65% | 529,398 | 1.37M | Sep 29, 2024 |
| Mission Wealth Management, LLC | 1.58% | 509,517 | 1.31M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.02% | 328,778 | 848.25K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.88% | 927,841 | 2.39M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.31% | 420,658 | 1.09M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.54% | 172,262 | 444.44K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.22% | 72,221 | 186.33K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.17% | 53,550 | 138.16K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 41,099 | 106.03K | Oct 30, 2024 |